We’re proud to share that our landmark clinical validation study, published earlier this year in Breast Cancer Research and Treatment, has been recognised as one of the journal’s top-performing articles, ranked in the 97th percentile for popularity.
The study highlights ground-breaking findings:
Digistain® demonstrates equivalent accuracy to incumbent technologies for the risk classification of HR+, HER2- breast cancer.
This achievement emphasises the potential of Digistain® to transform breast cancer diagnostics and improve outcomes for patients worldwide.
Dive into the details of our study and findings here:
